iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

NCT03350126 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Cancer Colorectal

Interventions

DRUG: Ipilimumab 200 MG in 40 ML Injection
DRUG: Nivolumab 10 MG/ML

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]